Currently, there is no approved targeted therapy option for treatment naïve patients with AML harboring a FLT3 mutation ineligible for intensive therapy. Konopleva and colleagues investigated the efficacy of venetoclax plus azacitidine in an FLT3-mutated AML population and reported that the remission rates and OS among patients with or without FLT3 mutation were similar, suggesting that venetoclax and azacitidine maybe be used for treatment naïve AML patients who are ineligible for intensive chemotherapy regimens irrespective of FLT3 mutations. They also observed higher remission rates among patients exhibiting both FLT3-ITD and TKD mutations; however, the impact on OS warrants further investigation.
Approximately 20% of patients with AML have IDH mutations. Preliminary data suggests they have better responses to venetoclax-based regimens. Pollyea and colleagues investigated the efficacy of venetoclax plus azacitidine in patients harboring IDH1/2 mutations. The responses and OS among these patients were superior compared to azacitidine alone. Furthermore, patients with...
